Glenview Capital Management has grown into one of the more prominent long-only hedge funds in the United States, known for its high-conviction, research-intensive approach. The fund typically holds between 20 and 40 stocks, concentrating capital in its highest-conviction ideas rather than spreading exposure broadly across the market. Robbins often targets companies in the healthcare, technology, consumer, and industrials sectors where he sees mispricing between current market sentiment and long-term intrinsic value. Public filings and investor letters highlight Glenview's emphasis on understanding business models deeply, engaging with management, and maintaining a long-term investment horizon measured in years rather than quarters.
Assets Under Management and Fund Structure
Glenview Capital Management's assets under management have fluctuated over the years as investors have joined or redeemed capital, with the fund's total AUM reported in the range of several billion dollars based on the most recent public disclosures. The fund operates with a traditional hedge fund fee structure that includes a management fee and a performance fee, the latter typically tied to returns above a hurdle rate or high-water mark. Glenview's private structure means that detailed holdings are not as transparent as those of public funds, but periodic investor letters and regulatory filings provide insight into the portfolio's size and direction.
Glenview's AUM has been shaped by both strong performance periods and periods of underperformance relative to broader equity markets, which has influenced capital flows from institutional limited partners. The fund's size allows it to take meaningful positions in large-cap stocks while still maintaining the flexibility to adjust exposure to sectors and individual names as investment theses evolve. Larry Robbins has publicly stated that Glenview aims to deliver attractive risk-adjusted returns over full market cycles rather than chase short-term rankings, a philosophy that has helped the fund retain a loyal investor base through multiple market environments.
Investment Strategy and Major Holdings
Glenview Capital Management's investment strategy centers on deep fundamental research, concentrated positions, and a long-term perspective, with the portfolio often anchored by large stakes in companies that Larry Robbins and his team believe are undervalued or positioned for durable growth. The fund has held significant positions in companies across the healthcare and technology sectors, including stakes in firms involved in medical devices, pharmaceuticals, and software, as well as consumer and industrial businesses with strong brands and pricing power. Public 13F filings and investor letters have shown Glenview's willingness to increase or decrease positions based on changes in valuation, business fundamentals, and management execution.
Glenview's portfolio has included exposure to companies in the healthcare space, with the fund having held positions in medical device and pharmaceutical companies that align with its focus on high-quality businesses with sustainable competitive advantages. The fund has also been known to take positions in technology and consumer companies where management teams are executing clear strategic visions, and it has occasionally engaged with company boards to advocate for capital allocation changes that could enhance shareholder value. While Glenview is not as widely followed as some of the largest public hedge funds, its concentrated approach and long-term horizon have drawn comparisons to the investment philosophies of other well-known long-only managers who prioritize business quality and margin of safety.
Sector Focus and Position Sizing
Glenview's sector allocation has historically favored healthcare and technology, with the fund often holding a smaller number of large positions that represent